I'm sorry it was questions.
June 24
I don’t have any doctor share on the topic of diabetes and CLL. I think you may want to post it in the main Q & A as its own question. I have not gotten a response to my questions. Yours may not been here.
June 24
I received a notification that you had replied to my question. I am only seeing your question, though, asking how diabetes is connected to CLL. Am I missing your reply? If you are asking me that question, I did not know there was a connection. Not aware of one. Maybe someone else can answer?
June 23
How is diabetes is connected to CLL
June 23
Having unmutated IGHV CLL with an 11q deletion is definitely something others in the community have navigated. A MyLeukemiaTeam member shared a similar combination of genetic factors and found connecting with others helped them feel less alone in understanding what it means for their outlook.
Here's what's generally known Show Full Answer
Having unmutated IGHV CLL with an 11q deletion is definitely something others in the community have navigated. A MyLeukemiaTeam member shared a similar combination of genetic factors and found connecting with others helped them feel less alone in understanding what it means for their outlook.
Here's what's generally known about your specific genetic profile:
Unmutated IGHV:
- Associated with a less favorable outlook compared to mutated IGHV
- CLL cells tend to be more aggressive and harder to treat
- Lower rates of complete remission compared to mutated IGHV
11q Deletion:
- Linked to a worse prognosis
- Often associated with more aggressive disease progression
- Can mean lymph nodes enlarge more significantly
13q Deletion:
- Actually considered a more favorable prognostic factor
- Often associated with slower-growing CLL Given this profile, treatment decisions are important to discuss closely with your doctor. Current treatment options often include:
- Targeted therapies like BTK inhibitors (e.g., ibrutinib) or BCL-2 inhibitors — these are now the preferred first-line treatments
- Immunotherapy for CLL that returns after other treatments
- Clinical trials, which may be especially worth exploring given higher-risk genetic features
Your doctor may also use the CLL International Prognostic Index (CLL-IPI) to help determine your risk level and guide treatment timing. Starting treatment early isn't always necessary, but your genetic profile makes close monitoring especially important.
Always discuss any new or worsening symptoms with your care team promptly.
June 14
Join
Your Privacy Choices
